Form 4: Relay Therapeutics Director Alexis Borisy Acquires Over 136,000 Stock Options

Relay Therapeutics, Inc. Director Alexis Borisy has acquired 136,681 stock options with an exercise price of $3.36, as reported in a recent SEC Form 4 filing.

Summary

• Alexis Borisy, a Director of Relay Therapeutics, Inc. (RLAY), acquired 136,681 stock options.
• The transaction occurred on June 6, 2025.
• Each option has an exercise price of $3.36.
• The options vest in full on the earlier of the first anniversary of the grant date (June 6, 2026) or the date of the next annual meeting of stockholders following the grant date.
• The options expire on June 5, 2035.
• Following this transaction, Mr. Borisy beneficially owns 136,681 derivative securities directly.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it indicates confidence in the company's future prospects and aligns the director's interests with shareholders. It's a standard compensation mechanism, not an extraordinary event, hence a moderately positive score.

Positives

• The acquisition of stock options by a director can signal confidence in the company's future performance and alignment of interests with shareholders.
• The options have a long expiration date (June 5, 2035), providing a significant window for potential value realization.

Future Outlook

The acquired stock options are subject to a vesting schedule, indicating that the director's full beneficial ownership of these shares is contingent upon continued service or the occurrence of specific corporate events (annual meeting) in the future.

Management Comments

• The filing indicates that the transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

Equity grants, such as stock options, are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector, to align their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice for executive and board compensation across various industries, including biotechnology, aligning with common corporate governance practices.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is typical for director equity awards, aiming to incentivize continued board service and strategic oversight.

Related Party Transactions

• The transaction involves the grant of stock options to Alexis Borisy, a Director of Relay Therapeutics, Inc., which constitutes a related-party transaction as it is an equity award to an insider.

Stakeholder Impact

• Shareholders may view this insider acquisition as a positive signal, suggesting that a key director believes in the company's future growth and value.
• The equity grant aligns the director's financial incentives with the long-term performance of the company, potentially benefiting all stakeholders through improved governance and strategic decisions.

Next Steps

• The options will vest in full on the earlier of June 6, 2026, or the date of the next annual meeting of stockholders following June 6, 2025.

Key Dates

Keywords

Relay Therapeutics, RLAY, Stock Option, Insider Transaction, Form 4, Alexis Borisy, Director, Equity Grant, Beneficial Ownership